-
1
-
-
0017701219
-
Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol
-
Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252(11), 3578-3581 (1977
-
(1977)
J. Biol. Chem
, vol.252
, Issue.11
, pp. 3578-3581
-
-
Abuchowski, A.1
Van Es, T.2
Palczuk, N.C.3
Davis, F.F.4
-
3
-
-
0033928514
-
Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs
-
Reddy KR. Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs. Ann. Pharmacother. 34(7-8), 915-923 (2000
-
(2000)
Ann. Pharmacother
, vol.34
, Issue.7-8
, pp. 915-923
-
-
Reddy, K.R.1
-
4
-
-
0000017353
-
Phase II trial of branched PEG (40 kDa interferon α-2a for patients with advanced renal cell carcinoma (RCC)
-
Motzer R, Thompson J, Gurney H et al. Phase II trial of branched PEG (40 kDa interferon α-2a for patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 20, 180a (2001
-
(2001)
Proc. Am. Soc. Clin. Oncol
, vol.20
, pp. 180
-
-
Motzer, R.1
Thompson, J.2
Gurney, H.3
-
5
-
-
0036087485
-
Novel effects with polyethylene glycol modified pharmaceuticals
-
Blackwell S.
-
Yowell SL, Blackwell S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat. Rev. 28(Suppl. A), 3-6 (2002
-
(2002)
Cancer Treat. Rev
, vol.28
, Issue.SUPPL. A
, pp. 3-6
-
-
Yowell, S.L.1
-
6
-
-
0036083609
-
Pegylation: Engineering improved pharmaceuticals for enhanced therapy
-
Molineux G. Pegylation: Engineering improved pharmaceuticals for enhanced therapy. Cancer Treat. Rev. 28(Suppl. A), 13-16 (2002
-
(2002)
Cancer Treat. Rev
, vol.28
, Issue.SUPPL. A
, pp. 13-16
-
-
Molineux, G.1
-
7
-
-
0029128861
-
PEGaspargase versus asparaginase in adult ALL: A pharmacoeconomic assessment
-
Peters BG, Goeckner BJ, Ponzillo JJ, Velasquez WS, Wilson AL. PEGaspargase versus asparaginase in adult ALL: A pharmacoeconomic assessment. Formulary 30(7), 388-393 (1995
-
(1995)
Formulary
, vol.30
, Issue.7
, pp. 388-393
-
-
Peters, B.G.1
Goeckner, B.J.2
Ponzillo, J.J.3
Velasquez, W.S.4
Wilson, A.L.5
-
8
-
-
33750850799
-
Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil
-
Vanni T, Fonseca BA, Polanczyk CA. Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil. HIV Clin. Trials 7(4), 194-202 (2006
-
(2006)
HIV Clin. Trials
, vol.7
, Issue.4
, pp. 194-202
-
-
Vanni, T.1
Fonseca, B.A.2
Polanczyk, C.A.3
-
9
-
-
0032529420
-
Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma
-
Bennett CL, Golub RM, Stinson TJ et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18(5), 460-465 (1998
-
(1998)
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol
, vol.18
, Issue.5
, pp. 460-465
-
-
Bennett, C.L.1
Golub, R.M.2
Stinson, T.J.3
-
10
-
-
0033427746
-
Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma
-
Hjortsberg C, Persson U, Lidbrink E, Bennett C. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. Acta Oncol. 38(8), 1063-1067 (1999
-
(1999)
Acta Oncol
, vol.38
, Issue.8
, pp. 1063-1067
-
-
Hjortsberg, C.1
Persson, U.2
Lidbrink, E.3
Bennett, C.4
-
11
-
-
34249791805
-
Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/ dexamethasone versus doxorubicin/ vincristine/ dexamethasone in patients with newly diagnosed multiple myeloma
-
Porter CA, Rifkin RM. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/ dexamethasone versus doxorubicin/ vincristine/dexamethasone in patients with newly diagnosed multiple myeloma. Clin. Lymphoma Myeloma 7(Suppl. 4), S150-S155 (2007
-
(2007)
Clin. Lymphoma Myeloma
, vol.7
, Issue.SUPPL. 4
-
-
Porter, C.A.1
Rifkin, R.M.2
-
12
-
-
70349897133
-
The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK
-
Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl. Health Econ. Health Policy 7(3), 193-205 (2009
-
(2009)
Appl. Health Econ. Health Policy
, vol.7
, Issue.3
, pp. 193-205
-
-
Liu, Z.1
Doan, Q.V.2
Malin, J.3
Leonard, R.4
-
13
-
-
66949127931
-
Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States
-
Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin. Ther. 31(5), 1092-1104 (2009
-
(2009)
Clin. Ther
, vol.31
, Issue.5
, pp. 1092-1104
-
-
Lyman, G.H.1
Lalla, A.2
Barron, R.L.3
Dubois, R.W.4
-
14
-
-
41549115442
-
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy
-
Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 11(2), 172-179 (2008
-
(2008)
Value Health
, vol.11
, Issue.2
, pp. 172-179
-
-
Eldar-Lissai, A.1
Cosler, L.E.2
Culakova, E.3
Lyman, G.H.4
-
15
-
-
4444288448
-
Cost-effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C
-
Sullivan SD, Jensen DM, Bernstein DE et al. Cost-effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C. Am. J. Gastroenterol. 99(8), 1490-1496 (2004
-
(2004)
Am. J. Gastroenterol
, vol.99
, Issue.8
, pp. 1490-1496
-
-
Sullivan, S.D.1
Jensen, D.M.2
Bernstein, D.E.3
-
16
-
-
2142695339
-
A health economic model to assess the long term effects and cost-effectiveness of PEG IFN α-2a in hepatitis C virus infected patients
-
Annemans L, Warie H, Nechelput M, Peraux B. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN α-2a in hepatitis C virus infected patients. Acta Gastroenterol. Belg. 67(1), 1-8 (2004
-
(2004)
Acta Gastroenterol. Belg
, vol.67
, Issue.1
, pp. 1-8
-
-
Annemans, L.1
Warie, H.2
Nechelput, M.3
Peraux, B.4
-
17
-
-
33749670275
-
Adefovir dipivoxil and PEG interferon α-2a for the treatment of chronic hepatitis B: A systematic review and economic evaluation
-
iii-iv, xi-xiv
-
Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and PEG interferon α-2a for the treatment of chronic hepatitis B: A systematic review and economic evaluation. Health Technol Assess. 10(iii-iv, xi-xiv), 1-183 (2006
-
(2006)
Health Technol Assess
, vol.10
, pp. 1-183
-
-
Shepherd, J.1
Jones, J.2
Takeda, A.3
Davidson, P.4
Price, A.5
-
18
-
-
77956258983
-
PATRONUS Investigators Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin β versus darbepoetin α administered monthly: A randomized comparative trial
-
Carrera F, Lok CE, de Francisco A et al.; PATRONUS Investigators. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin β versus darbepoetin α administered monthly: A randomized comparative trial. Nephrol. Dial. Transplant. 25(12), 4009-4017 (2010
-
(2010)
Nephrol. Dial. Transplant
, vol.25
, Issue.12
, pp. 4009-4017
-
-
Carrera, F.1
Lok, C.E.2
De Francisco, A.3
-
19
-
-
0003458828
-
-
Oxford University Press NY, USA Neupogen® Package Insert. Amgen Inc Thousand Oaks CA, USA.
-
Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, NY, USA (2005 Neulasta®, package insert. Amgen Inc, Thousand Oaks, CA, USA
-
(2005)
Methods for the Economic Evaluation of Health Care Programmes
-
-
Drummond, M.F.1
Sculpher, M.J.2
Torrance, G.W.3
O'Brien, B.J.4
Stoddart, G.L.5
-
20
-
-
77649126999
-
Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: A cost-effectiveness analysis for Germany
-
Sehouli J, Goertz A, Steinle T et al. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: A cost-effectiveness analysis for Germany]. Dtsch. Med. Wochenschr. 135(9), 385-389 (2010
-
(2010)
Dtsch. Med. Wochenschr
, vol.1359
, pp. 385-389
-
-
Sehouli, J.1
Goertz, A.2
Steinle, T.3
-
21
-
-
78651342871
-
Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
-
Samaras P, Blickenstorfer M, Siciliano RD et al. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Ann. Hematol. 90(1), 89-94 (2011
-
(2011)
Ann. Hematol
, vol.90
, Issue.1
, pp. 89-94
-
-
Samaras, P.1
Blickenstorfer, M.2
Siciliano, R.D.3
-
22
-
-
70350109377
-
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim or chemotherapy-induced neutropenia
-
Heaney ML, Toy EL, Vekeman F et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim or chemotherapy-induced neutropenia. Cancer 115(20), 4839-4848 (2009
-
(2009)
Cancer
, vol.115
, Issue.20
, pp. 4839-4848
-
-
Heaney, M.L.1
Toy, E.L.2
Vekeman, F.3
-
23
-
-
84871490150
-
Cost-minimization analysis of once-percycle fixed-dose administration of PEGfilgrastim versus dail filgrastrim for the prophylaxis of chemotherapy-induced febrile neutropenia in Brazil
-
20-23 October
-
Lago S, Nasciben V, Saggia M. Cost-minimization analysis of once-percycle fixed-dose administration of PEGfilgrastim versus dail filgrastrim for the prophylaxis of chemotherapy-induced febrile neutropenia in Brazil. Presented at: ISPOR Tenth Annual European Congress. Dublin, Ireland, 20-23 October 2007
-
(2007)
Presented at: ISPOR Tenth Annual European Congress. Dublin Ireland
-
-
Lago, S.1
Nasciben, V.2
Saggia, M.3
-
24
-
-
84871495773
-
Primary prophylaxis with PEGfilgrastim is cost-saving compared with filgrastim for breast cancer in Spain
-
Copenhagen Denmark 28-31 October
-
Mayordomo J, Pousa A, Arocho R, Doan QV, Dubois RW, Liu Z. Primary prophylaxis with PEGfilgrastim is cost-saving compared with filgrastim for breast cancer in Spain. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28-31 October 2006
-
(2006)
Presented at: ISPOR Ninth Annual European Congress
-
-
Mayordomo, J.1
Pousa, A.2
Arocho, R.3
Doan, Q.V.4
Dubois, R.W.5
Liu, Z.6
-
25
-
-
84871477246
-
Analysis on cost difference between daily filgrastim and one per cycle pegfilgrastim for prophylaxis against chemotherapy-induced neutropenia in France and Germany. Presented at: ISPOR Sixth Annual European Congress. Barcelona
-
9-11 November
-
Suczs T, Standaert B, Lu Z. Analysis on cost difference between daily filgrastim and one per cycle pegfilgrastim for prophylaxis against chemotherapy-induced neutropenia in France and Germany. Presented at: ISPOR Sixth Annual European Congress. Barcelona, Spain, 9-11 November 2003
-
(2003)
Spain
-
-
Suczs, T.1
Standaert, B.2
Lu, Z.3
-
26
-
-
84871528849
-
Primary prophylaxis with pegfilgrastim is cost-saving compared with filgrastim for breast cancer in france
-
Copenhagen Denmark 28-31 October
-
Bogillot O, Dubois R, Doan Q, Liu Z, Heissel A, Di Palma M. Primary prophylaxis with PEGfilgrastim is cost-saving compared with filgrastim for breast cancer in France. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28-31 October 2006
-
(2006)
Presented at: ISPOR Ninth Annual European Congress
-
-
Bogillot, O.1
Dubois, R.2
Doan, Q.3
Liu, Z.4
Heissel, A.5
Di Palma, M.6
-
27
-
-
84871479151
-
Cost utility analysis of primary prophylaxis with pegfilgrastim versus filgrastim for breast cancer in the UK
-
Copenhagen Denmark 28-31 October
-
Booth P, Dubois R, Doan Q, Liu Z. Cost utility analysis of primary prophylaxis with pegfilgrastim versus filgrastim for breast cancer in the UK. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28-31 October 2006
-
(2006)
Presented at: ISPOR Ninth Annual European Congress
-
-
Booth, P.1
Dubois, R.2
Doan, Q.3
Liu, Z.4
-
28
-
-
84871494568
-
Cost-effectivenss of pegfligrastim versus filgrastim after high-dose chemctherapy and autologous stem cell transplantation in patients with lymphoma nad myeloma
-
Presented at: 5-8 November 2011
-
Perrier L, Lefranc A, Quittet P et al. Cost-effectivenss of pegfligrastim versus filgrastim after high-dose chemctherapy and autologous stem cell transplantation in patients with lymphoma nad myeloma. Presented at: ISPOR Fourteenth Annual European Congress, Madrid, Spain, 5-8 November 2011
-
ISPOR Fourteenth Annual European Congress, Madrid, Spain
-
-
Perrier, L.1
Lefranc, A.2
Quittet, P.3
-
29
-
-
84871517054
-
Primary prophylaxis against febrile neutropenia with PEGfilgrastim is cost-effective compared with filgrastim in non-Hodgkin's lymphoma patients receiving chop-21 in Italy
-
Dublin Ireland 20-23 October
-
Chiroli S, Health Ciceri F, Atchison C, Malin J, Doan Q. Primary prophylaxis against febrile neutropenia with PEGfilgrastim is cost-effective compared with filgrastim in non-Hodgkin's lymphoma patients receiving chop-21 in Italy. Presented at: ISPOR Tenth Annual European Congress. Dublin, Ireland, 20-23 October 2007
-
(2007)
Presented at: ISPOR Tenth Annual European Congress
-
-
Chiroli, S.1
Health Ciceri, F.2
Atchison, C.3
Malin, J.4
Doan, Q.5
-
30
-
-
84871499362
-
Cost-effectiveness of primary prophylaxis with PEGfilgrastim versus filgrastim for reducing incidence of febrile neutropenia in non-Hodgkin lymphoma and stage II breast cancer patients in Germany
-
Prague Czech Republic 6-9 November 2010
-
Taylor D, Ozer-Deniz S, Hill G, Skornicki M, Danel A, Erika K. Cost-effectiveness of primary prophylaxis with PEGfilgrastim versus filgrastim for reducing incidence of febrile neutropenia in non-Hodgkin lymphoma and stage II breast cancer patients in Germany. Presented at: ISPOR 13th Annual European Conference. Prague, Czech Republic, 6-9 November 2010
-
Presented at: ISPOR 13th Annual European Conference
-
-
Taylor, D.1
Ozer-Deniz, S.2
Hill, G.3
Skornicki, M.4
Danel, A.5
Erika, K.6
-
31
-
-
84871489771
-
Cost effectiveness of primary prophylaxis with pegfilgrastim or filgrastim in the medical treatment of breast cancer in Italy
-
Copenhagen Denmark 28-31 October
-
Chiroli S, Dubois R, Doan Q et al. Cost effectiveness of primary prophylaxis with pegfilgrastim or filgrastim in the medical treatment of breast cancer in Italy. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28-31 October 2006
-
(2006)
Presented at: ISPOR Ninth Annual European Congress
-
-
Chiroli, S.1
Dubois, R.2
Doan, Q.3
-
32
-
-
67649126886
-
Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients
-
Danova M, Chiroli S, Rosti G, Doan QV. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori 95(2), 219-226 (2009
-
(2009)
Tumori
, vol.95
, Issue.2
, pp. 219-226
-
-
Danova, M.1
Chiroli, S.2
Rosti, G.3
Doan, Q.V.4
-
33
-
-
64249170087
-
Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States
-
Lyman G, Lalla A, Barron R, Dubois RW. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr. Med. Res. Opin. 25(2), 401-411 (2009
-
(2009)
Curr. Med. Res. Opin
, vol.25
, Issue.2
, pp. 401-411
-
-
Lyman, G.1
Lalla, A.2
Barron, R.3
Dubois, R.W.4
-
34
-
-
84871474936
-
Primary prophylaxis against febrile neutropenia with PEGfilgrastim is cost-effective compared with filgrastim in non-Hodgkin's lymphoma patients receiving CHOP-21 in Spain
-
Dublin Ireland 20-23 October Doxil® Package Insert. Janssen Biotech Horsham PA USA. 38 Pegasys® Package Insert. Genentech South San Francisco CA USA. Pegasys®, package insert. Genentech, South San Francisco, CA, USA. 39 PegInteron®, package insert. Merck, Whitehouse Station, NJ, USA
-
Arocho R, Atchison C, Malin J. Primary prophylaxis against febrile neutropenia with PEGfilgrastim is cost-effective compared with filgrastim in non-Hodgkin's lymphoma patients receiving CHOP-21 in Spain. Presented at: ISPOR Tenth Annual European Congress. Dublin, Ireland, 20-23 October 2007 Doxil®, package insert. Janssen Biotech, Horsham, PA, USA PegInteron® Package Insertt Merck Whitehouse Station NJ USA.
-
(2007)
Presented at: ISPOR Tenth Annual European Congress
-
-
Arocho, R.1
Atchison, C.2
Malin, J.3
-
35
-
-
33746026313
-
Cost-effectiveness Of Peginterferon α-2a (40 KDa) Plus Ribavirin In Patients With HIV And Hepatitis C Virus Co-infection
-
Hornberger J, Torriani FJ, Dieterich DT et al. Cost-effectiveness of peginterferon α-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J. Clin. Virol. 36(4), 283-291 (2006
-
(2006)
J. Clin. Virol
, vol.36
, Issue.4
, pp. 283-291
-
-
Hornberger, J.1
Torriani, F.J.2
Dieterich, D.T.3
-
36
-
-
77749283196
-
Cost effectiveness of peginterferon α-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil
-
Fonseca MC, Araújo GT, Araújo DV. Cost effectiveness of peginterferon α-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil. Braz. J. Infect. Dis. 13(3), 191-199 (2009
-
(2009)
Braz. J. Infect. Dis
, vol.13
, Issue.3
, pp. 191-199
-
-
Fonseca, M.C.1
Araújo, G.T.2
Araújo, D.V.3
-
37
-
-
0038352047
-
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population
-
Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290(2), 228-237 (2003
-
(2003)
JAMA
, vol.290
, Issue.2
, pp. 228-237
-
-
Salomon, J.A.1
Weinstein, M.C.2
Hammitt, J.K.3
Goldie, S.J.4
-
38
-
-
9944225119
-
PEG interferon α-2a and-2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation
-
iii-iv
-
Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. PEG interferon α-2a and-2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol. Assess. 8(iii-iv), 1-125 (2004
-
(2004)
Health Technol. Assess
, vol.8
, pp. 1-125
-
-
Shepherd, J.1
Brodin, H.2
Cave, C.3
Waugh, N.4
Price, A.5
Gabbay, J.6
-
39
-
-
84871513114
-
The cost-effectiveness analysis of PEGinterferon α-2a and ribavirin versus interferon α-2b and ribavirin in chronic hepatitis C in Poland. Presented at: ISPOR Sixth Annual European Congress. Barcelona
-
9-11 November
-
Orlewska E, Juszczyk J. The cost-effectiveness analysis of PEGinterferon α-2a and ribavirin versus interferon α-2b and ribavirin in chronic hepatitis C in Poland. Presented at: ISPOR Sixth Annual European Congress. Barcelona, Spain, 9-11 November 2003
-
(2003)
Spain
-
-
Orlewska, E.1
Juszczyk, J.2
-
40
-
-
84871499088
-
Cost-effectiveness of PEGinterferon α-2a (40 kd for the treatment of chronic hepatitis B in Italy
-
Copenhagen Denmark 28-31 October
-
Eandi M, Iannazzo S, Pradelli L Cost-effectiveness of PEGinterferon α-2a (40 kd for the treatment of chronic hepatitis B in Italy. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28-31 October 2006
-
(2006)
Presented at: ISPOR Ninth Annual European Congress
-
-
Eandi, M.1
Iannazzo, S.2
Pradelli, L.3
-
41
-
-
84891685662
-
Health benefits of antiviral therapy for mild chronic hepatitis C: Randomised controlled trial and economic evaluation
-
UK Mild Hepatitis C Trial Investigators iii
-
Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: Randomised controlled trial and economic evaluation. Health Technol. Assess. 10(21), 1-113, iii (2006
-
(2006)
Health Technol. Assess
, vol.10
, Issue.21
, pp. 1-113
-
-
Wright, M.1
Grieve, R.2
Roberts, J.3
Main, J.4
Thomas, H.C.5
-
42
-
-
84871525641
-
Cost-effectiveness analysis of PEG interferons combined with ribavirin in the treatment of hepatitis C
-
Barcelona Spain 9-11 November
-
Mar J, Antonanzas F, Velasco M et al. Cost-effectiveness analysis of PEG interferons combined with ribavirin in the treatment of hepatitis C. Presented at: ISPOR Sixth Annual European Congress. Barcelona, Spain, 9-11 November 2003
-
(2003)
Presented at: ISPOR Sixth Annual European Congress
-
-
Mar, J.1
Antonanzas, F.2
Velasco, M.3
-
43
-
-
0036214409
-
A pharmacoeconomic analysis of PEGaspargase versus native Escherichia coli l-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: The Children's Cancer Group study (CCG-1962
-
Kurre HA, Ettinger AG, Veenstra DL et al. A pharmacoeconomic analysis of PEGaspargase versus native Escherichia coli l-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: The Children's Cancer Group study (CCG-1962). J. Pediatr. Hematol. Oncol. 24(3), 175-181 (2002
-
(2002)
J. Pediatr. Hematol. Oncol
, vol.24
, Issue.3
, pp. 175-181
-
-
Kurre, H.A.1
Ettinger, A.G.2
Veenstra, D.L.3
-
44
-
-
84871509104
-
Cost-minimization analysis: Mircera (methoxypolytheylene glycol-epoetin β) vs. Anranesp (darbepoetin α) in patients with chronic kidney disease (CKD) who are not receiving haemodialysis, in Polish etting
-
24-27 October
-
Kawalec P, Kuzma J, Szkultecka-Debek M et al. Cost-minimization analysis: Mircera (methoxypolytheylene glycol-epoetin β) vs. Anranesp (darbepoetin α) in patients with chronic kidney disease (CKD) who are not receiving haemodialysis, in Polish etting. Presented at: ISPOR 12th Annual European Conference. Paris, France, 24-27 October 2009
-
(2009)
Presented at: ISPOR 12th Annual European Conference. Paris, France
-
-
Kawalec, P.1
Kuzma, J.2
Szkultecka-Debek, M.3
-
45
-
-
72949096583
-
Good research practices for measuring drug costs in cost-effectiveness analyses: A societal perspective: The ISPOR Drug Cost Task Force report-Part I.I
-
Garrison LP Jr, Mansley EC, Abbott TA 3rd, Bresnahan BW, Hay JW, Smeeding J Good research practices for measuring drug costs in cost-effectiveness analyses: A societal perspective: The ISPOR Drug Cost Task Force report-Part II. Value Health 13(1), 8-13 (2010
-
(2010)
Value Health
, vol.13
, Issue.1
, pp. 8-13
-
-
Garrison Jr., L.P.1
Mansley, E.C.2
Abbott III, T.A.3
Bresnahan, B.W.4
Hay, J.W.5
Smeeding, J.6
|